Alvotech SA DRC (ALVOsdb)

Currency in SEK
84.00
+0.90(+1.08%)
Closed·
ALVOsdb Scorecard
Full Analysis
Net income is expected to grow this year
ALVOsdb is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
83.1185.31
52 wk Range
81.02157.00
Key Statistics
Prev. Close
83.1
Open
83.11
Day's Range
83.11-85.31
52 wk Range
81.02-157
Volume
3.65K
Average Volume (3m)
176.24K
1-Year Change
-
Book Value / Share
-10.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALVOsdb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Alvotech SA DRC Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Industry
-
Sector
-
Employees
1012
Market
Sweden

Compare ALVOsdb to Peers and Sector

Metrics to compare
ALVOsdb
Peers
Sector
Relationship
P/E Ratio
28.0x−1.6x−0.5x
PEG Ratio
0.240.000.00
Price/Book
−8.9x4.1x2.6x
Price / LTM Sales
4.6x5.8x3.2x
Upside (Analyst Target)
-331.4%42.7%
Fair Value Upside
Unlock22.8%5.8%Unlock

Earnings

Latest Release
May 07, 2025
EPS / Forecast
3.39 / --
Revenue / Forecast
1.29B / --
EPS Revisions
Last 90 days

ALVOsdb Income Statement

FAQ

What Stock Exchange Does Alvotech DRC Trade On?

Alvotech DRC is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Alvotech DRC?

The stock symbol for Alvotech DRC is "ALVOsdb."

What Is the Alvotech DRC Market Cap?

As of today, Alvotech DRC market cap is 25.72B.

What Is Alvotech DRC's Earnings Per Share (TTM)?

The Alvotech DRC EPS (TTM) is 0.35.

When Is the Next Alvotech DRC Earnings Date?

Alvotech DRC will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is ALVOsdb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Alvotech DRC Stock Split?

Alvotech DRC has split 0 times.

How Many Employees Does Alvotech DRC Have?

Alvotech DRC has 1012 employees.

What is the current trading status of Alvotech DRC (ALVOsdb)?

As of 23 Jul 2025, Alvotech DRC (ALVOsdb) is trading at a price of 84.00, with a previous close of 83.10. The stock has fluctuated within a day range of 83.11 to 85.31, while its 52-week range spans from 81.02 to 157.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.